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Background & Aims: Brain death-associated inﬂammatory Introduction
response contributes to increased risk of impaired early liver allo-
graft function, which might be counterbalanced by steroid pre-
treatment of the organ donor. The aim of this randomized
controlled trial was to elucidate whether steroid pretreatment
of liver donors improves early liver allograft function, prevents
rejection and prolongs survival.
Methods: A placebo-controlled blinded randomized clinical trial
was performed in three different centers in Austria and Hungary
between 2006 and 2008. Ninety deceased organ donors received
either 1000 mg of methylprednisolone or placebo 6 h before
recovery of organs. The primary end point was the concentration
slope of transaminases within the ﬁrst week. The secondary end
point included survival and biopsy-conﬁrmed acute rejection
(BCAR) within 3 years after transplantation.
Results: Of the 90 randomized donors, 83 recipients were eligible
for study. The trajectories of ALT and AST were not different
between treatments (p = 0.40 and p = 0.13, respectively). Eight
subjects died in the steroid and 13 in the placebo group within
3 years after engraftment (RR = 0.63 95% CI [0.29, 1.36],
p = 0.31). Eleven recipients experienced biopsy-conﬁrmed rejec-
tion (BCAR) in the steroid and 11 in the placebo group
(RR = 1.02 95% CI [0.50, 2.10], p = 1.00). No effect modiﬁcation
could be identiﬁed in the predeﬁned strata of donor age, sex, cold
ischemic time, and cause of donor death.
Conclusions: Steroid pretreatment of organ donors did not
improve outcomes after liver transplantation.
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by Elsevier B.V. All rights reserved.Journal of Hepatology 20
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liver disease. However, a raising demand for liver transplant
organs has increased the median waiting time for liver allografts
in the Eurotransplant region from 4 months in 2000 to 14 months
in 2009 [1]. Even worse, approximately 20% of all patients on the
waiting list for liver transplantation died in 2009.
Thus donor criteria have been liberalized in the last decade as a
consequence of the imbalance between supply and demand. For
example, the median age of liver donors increased from 26 to
52 years between 1990 and2009.While donor age has been consid-
ered a major risk factor for long time graft survival [2,3], there is an
increasing evidence that also consequences of donor brain death in
the graft might exert adverse effects on transplant recipients.
It has been shown in kidney transplantation that graft survival
from living donors is signiﬁcantly longer when compared to
deceased donor allografts [4,5]. Furthermore, brain death triggers
a complex series of pathophysiological changes that also drive
alterations of gene expression in transplant organs [6–10],
althoughdonor organsderived from livingor deceaseddonors can-
not be distinguished on a morphological basis. We previously
showed in kidney grafts that gene expression proﬁles derived from
deceased organs are characterized by a severe pro-inﬂammatory
state which is not observed in organs from living donors [11].
Recently, we elucidated that pretreatment of deceased organ
donors with corticosteroids led to a signiﬁcant reduction of the
molecular inﬂammation signature in transplant kidneys even
though the rate of delayed graft function remained unchanged
[12].
The inﬂuence of steroid pretreatment on the outcome after
liver transplantation has been evaluated in a previous study
[13]. In this publication, the authors claimed that steroid donor
treatment signiﬁcantly ameliorated ischemia reperfusion injury
determined by AST levels on day one after transplantation. How-
ever, the effect of steroid pretreatment on the genome wide
inﬂammatory signature as well as the trajectories of transami-
nases and hard long-term outcomes remained elusive.
Thus, the goal of the present study was to test in a blinded,
randomized, placebo-controlled clinical trial whether steroid
pretreatment of the deceased organ donor caused a reduced12 vol. 56 j 1305–1309
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release of transaminase from the donor liver and subsequently
less rejection and longer survival.Materials and methods
Study design
The liver grafts recovered from multiorgan donors of our recently published ran-
domized, blinded, placebo-controlled trial were evaluated [12]. The trial is regis-
tered under controlled-trials.com registration number ISRCTN78828338. Out of
the total eligible donors (n = 269), 90 liver donors (39 from Vienna, 39 from Buda-
pest and 5 from Linz) were randomized equally in the steroid or placebo group. The
detailed CONSORT criteria can be found in Kainz et al. [12]. Brieﬂy, after brain death
was declared, deceased donors received either a single injection of 1000 mgmeth-
ylprednisolone or placebo (0.9% saline) between 6 and 3 h before organ recovery.
All organs were perfused with a histidine-ketoglutarate preservation solution dur-
ing organ procurement. Liver transplant recipients from the transplant centers in
Vienna (Austria) and Budapest (Hungary) were included in our trial. The donor
demographics were collected at the study website http://www.meduniw-
ien.ac.at/nephrogene/trials/ and the liver recipient demographics and follow-up
data of the recipient were collected by the local transplant coordinators.
Donors were equally randomized to steroid or placebo treatment based on a
permuted block design with block sizes of four (https://www.meduniwien.ac.at/
randomizer). Central randomization was stratiﬁed for donor age above 50 years
through our study website and concealed until data analysis. The randomization
order did not have a repeating sequence and the randomization code was not
revealed to recipients or investigators. The local transplant coordinators, enrolled
donors, recipients and investigators were blinded for the allograft treatment.
The study protocol was approved by the institutional review board (Ethical
Committee of the Medical University of Vienna, Vienna, Austria [study protocol
EK-067/2005; to be found at http://ohrp.cit.nih.gov/search]), TUKEB-Hungary
and Eurotransplant (study protocol 6021KAC06) at each study site.
Outcomes and sample size calculation
Our primary end point was the serum level trajectories of transaminases (alanine
transaminase (ALT) and aspartate transaminase (AST)) within the ﬁrst week after
engraftment.
We calculated a detectable difference in the slopes of 0.65 between the
groups at a standard deviation of 0.3, a correlation coefﬁcient of 0.7 in the
sequential individual measurements and the assumption that a slope of the log
transformed AST levels in the ﬁrst week is 0.5. Study power was 80% at an alpha
value of 0.05 assuming a 10% drop-out rate to detect such difference. Exclusion
criteria were fulminant liver failure, multiorgan transplantation or retransplanta-
tion and HIV-positive recipients.
Liver speciﬁc data, which were recorded daily in the ﬁrst week of the trial,
included gamma glutamyl transpeptidase (GGT), alkaline phosphatase (AP), albu-
min as well as total bilirubin.
The secondary end point included graft loss, mortality and BCAR (Rejection
Activity Index (RAI) score P3) within 3 years after transplantation.Donors randomly assigned (n = 90)
Assigned to steroid group (n = 46)
Recipients (n = 46)
Excluded (n = 5)
2 re-transplantations
1 simultaneous
   kidney and liver
2 high urgency
   transplantations
Excluded (n = 2)
1 simultaneous
   kidney and liver
1 high urgency
   transplantation
Eligible recipients (n = 41)
Assigned to placebo group (n = 44)
Recipients (n = 44)
Eligible recipients (n = 42)
Fig. 1. CONSORT ﬂowchart of organ donor and liver graft recipients.
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time, and cause of donor death were evaluated by interaction analyses.Statistical analysis
Demographic baseline characteristics were compared using t tests for continuous
data and Chi-square tests or Fisher exact tests for categorical data. Trajectories of
various liver parameters after transplantation were analyzed using a linear mixed
model with time, therapy as well as the transplantation center as independent
variables. Kaplan–Meier plots were used to visualize time to acute rejection epi-
sodes and the combined graft loss/death. Differences between groups were calcu-
lated by the log-rank test. Data are provided as mean ± SD if not otherwise
indicated. p values <0.05 were considered to be statistically signiﬁcant. All anal-
yses were performed with SAS for Windows 9.2 (Cary, NJ, USA).Results
Baseline characteristics of organ donors and recipients
Of the 90 randomized donors, seven allografts were allocated to
recipients with study exclusion criteria (2 retransplant, 2 simulta-
neous kidney and liver, 3 high urgency transplantations). Of the
remaining 83 donor organs, 41 organs were procured from steroid
treated and 42 from placebo treated donors between 2006 and
2008 (see CONSORT ﬂowchart in Fig. 1). Age, sex and clinical indi-
ces of donors and recipients are provided in Table 1. Mean donor
age and recipient age were not different in both groups (47 ± 12
and 48 ± 13 years in the placebo group vs. 46 ± 12 and 49 ± 9 years
in the treatment group). Accordingly,meanMELD score of the reci-
pient and cold ischemic time did not reveal signiﬁcant differences
between the study arms (16 ± 6 and 440 ± 123 min in the control
group vs. 15 ± 6 and 444 ± 136 min in the steroid group).
The immunosuppressive regime of all subjects included 40 mg
dexamethasone intraoperatively, 3 days of ATG induction (Thy-
moglobuline, Genzyme 2.5 mg/kg/d) and CNI maintenance ther-
apy. Rejections were treated with 3 days of 500 mg prednisolone.Primary and secondary study end points
Biochemical indicators of liver cell necrosis over the ﬁrst week
are depicted in Fig. 2. Trajectories of alanine and aspartate trans-
aminases (ALT and AST) were not different between the two
treatment groups (p = 0.40 and p = 0.13, respectively). Mean ALT
levels decreased between day 1 and day 7 post-transplantation
from 784 ± 1025 U/L to 156 ± 148 U/L in the steroid group while
levels decreased from 870 ± 904 U/L to 261 ± 402 U/L in the pla-
cebo group. Similarly, mean AST levels dropped from 1002 ± 1130
U/L to 59 ± 58 U/L in the steroid group compared to 1898 ± 3364
U/L to 140 ± 398 U/L in the placebo group.
Accordingly, the trajectories of glutamyl transpeptidase (GGT,
p = 0.75), total bilirubin (BIL, p = 0.14), serum albumin (ALB,
p = 0.32) and alkaline phosphatase (AP, p = 0.30) within 7 days
after transplantation were not different between the two groups.
The relative risk of mortality in the steroid compared to the
placebo group was 0.63 (95% CI [0.29, 1.36], p = 0.31). The relative
risk for BCAR in the steroid compared to the placebo arm was
1.02 (95% CI [0.50, 2.10], p = 1.00).
The probability of survival and BCAR episodes over a follow-
up period of 3 years was not statistically different in the two
treatment arms (Fig. 3A and B). In the ﬁrst year, 6 patients
(15%) experienced graft loss in the steroid group vs. 10 patientsvol. 56 j 1305–1309
Table 1. Demographic data of donors and recipients stratiﬁed by treatment.
Parameters Placebo 
(n = 42)
Steroid 
(n = 41)
Donor age (yr ± SD) 47 ± 12 46 ± 12
Donor sex (M/F) 27/15 23/18
Donor ICU (d ± SD) 4 ± 4 5 ± 6
No. of cardiac arrests 4 5
Donor AST (U/L ± SD) 46 ± 41 58 ± 75
Donor ALT (U/L ± SD) 31 ± 31 44 ± 70
INR 1.2 ± 0.2 1.3 ± 0.2
Vasopressor medication
Adrenaline 14 15
Noradrenaline 17 20
Dopamine 8 2
Recipient age (yr ± SD) 48 ± 13 49 ± 9
Recipient sex (M/F) 27/15 24/17
MELD score 16 ± 6 15 ± 6
Cold ischemic time (min ± SD) 440 ± 123 444 ± 136
Warm ischemic time (min ± SD) 56 ± 16 57 ± 20
Blood products
Packed red cells 27 24
Fresh frozen plasma 23 14
Virus-inactivated plasma 6 7
Packed plateletsa 15 6
Infections 17 11
Bile duct complications 3 2
1-wk serum creatinine (mg/dl ± SD) 1.15 ± 0.66 1.03 ± 0.47
Recipient ICU (d ± SD) 10 ± 13 8 ± 7
Total hospital stay (d ± SD) 22 ± 20 19 ± 17
ESLD diagnosis
HCV 16 15
HCC 6 7
Alcoholic cirrhosis 7 8
Autoimmune hepatitis 1 3
Primary biliary cirrhosis 3 1
Cryptogenic cirrhosis 4 0
Other 5 7
ap = 0.04 (Fisher’s exact test).
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Fig. 2. Trajectories of liver function parameters in the ﬁrst week after
transplantation. Mean values and standard errors of mean from day 1 to day 7
after transplantation are shown for (A) alanine transaminase (ALT) (p = 0.40), (B)
aspartate transaminase (AST) (p = 0.13), (C) glutamyl transpeptidase (GGT)
(p = 0.75), (D) serum albumin (ALB) (p = 0.32), (E) total bilirubin (BIL) (p = 0.14)
and (F) alkaline phosphatase (AP) (p = 0.30).
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Fig. 3. Kaplan–Meier estimates of (A) survival (p = 0.24) and (B) biopsy-
conﬁrmed rejection (log-rank p = 0.96) risks are shown for steroid pretreated
livers and placebo. The number of subjects at risk is provided above the x-axis.
Given p values were derived from log-rank tests. BCAR, biopsy-conﬁrmed
rejection; TX, transplantation.
JOURNAL OF HEPATOLOGY(24%) in the placebo group (p = 0.41). One graft loss in the pla-
cebo group did not lead to death because of high urgency retrans-
plantation. Acute rejection within the ﬁrst 3 months occurred in
10 recipients (24%) in the steroid group vs. 10 patients (24%) in
the placebo group (p = 1.00).
We did not ﬁnd any effect modiﬁcation for the variables donor
age, sex, cold ischemic time, and cause of donor death (Fig. 4).Discussion
Our study showed that systemic administration of 1000 mg
methylprednisolone to the deceased organ donor did not signiﬁ-Journal of Hepatology 2012cantly ameliorate liver allograft function or mortality or rejection
within the ﬁrst weeks after engraftment.
This result is in line with our observation that steroid pre-
treatment did not reduce the incidence or duration of acute renal
transplant failure in kidney allograft recipients [12]. On the other
hand, this ﬁnding contradicts a similar trial that has claimed a
protective positive effect of steroid treatment in deceased donorvol. 56 j 1305–1309 1307
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Fig. 4. Graft loss by various donor characteristics. Indicated p values represent
the interaction between treatment and characteristics.
Research Articleliver transplantation [13,14]. It is therefore essential to try to
explain these distinct results of both studies.
First, it seems necessary to clarify whether steroid administra-
tion was effective in terms of suppression of inﬂammation in the
donor organ. To address this question, we have previously shown
in kidney transplants, using genome wide expression proﬁling,
that steroid treatment results in a pronounced suppression of
inﬂammation/immune response-associated genes [12,15–17].
These data suggest that dose and timing of the blinded interven-
tion were chosen correctly and randomization worked ﬁne.
Furthermore, different experimental parameters between
both trials could eventually explain varying outcomes. Adminis-
tration of the corticosteroid was somewhat different since, in
our study, donors received one single shot of 1000 mg whereas
Kotsch et al. applied 250 mg initially followed by continuous
infusion of 100 mg/h. In addition, the primary study end points
were transaminases levels on day one post-transplantation in
the trial of Kotsch et al.while the present study evaluated the tra-
jectories of transaminases as a more stable measurement of a
treatment effect. Another difference was the number of study
sites, which has an effect on the balance of internal and external
validity, i.e. generalizability of ﬁndings. Both studies found no
signiﬁcant differences between rejection rates [13].
Our study, however, was not powered to detect a statistical
difference of transaminase trajectories between groups below
0.65. We considered a smaller difference in transaminase trajec-
tories not to be of sound clinical signiﬁcance. Donor organ quality
determined by donor age, which predicts early and long term
outcome [18], was not different between groups. A deﬁnitive
strength of our study is the evaluation of the steroid intervention
on hard study end points such as mortality and biopsy-conﬁrmed
rejection over a 3-year period.
In summary, liver ischemia reperfusion injury is obviously by
far more complex than expected, so that a reductionist view lim-
iting interventions to steroid pretreatment does not seem to be
successful. Thus, although the brain death-related immune
response might play an essential role during ischemia reperfu-
sion injury and subsequent transplant dysfunction, it seems that
this immune response itself is not a causative factor but that
other factors must exist. Further efforts are therefore required1308 Journal of Hepatology 2012in order to signiﬁcantly improve ischemia reperfusion injury in
the context of liver transplantation.Conﬂict of interest
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